[go: up one dir, main page]

AU2001244192A1 - Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction - Google Patents

Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction

Info

Publication number
AU2001244192A1
AU2001244192A1 AU2001244192A AU4419201A AU2001244192A1 AU 2001244192 A1 AU2001244192 A1 AU 2001244192A1 AU 2001244192 A AU2001244192 A AU 2001244192A AU 4419201 A AU4419201 A AU 4419201A AU 2001244192 A1 AU2001244192 A1 AU 2001244192A1
Authority
AU
Australia
Prior art keywords
pyrazinones
pyrido
phosphodiesterase
inhibitors
erectile dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244192A
Inventor
Ute Egerland
Norbert Hofgen
Thomas Kronbach
Degenhard Marx
Stefan Szelenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elbion GmbH
Original Assignee
Arzneimittelwerk Dresden GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arzneimittelwerk Dresden GmbH filed Critical Arzneimittelwerk Dresden GmbH
Publication of AU2001244192A1 publication Critical patent/AU2001244192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001244192A 2000-03-14 2001-03-06 Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction Abandoned AU2001244192A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10012373 2000-03-14
DE10012373A DE10012373A1 (en) 2000-03-14 2000-03-14 Treating erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, as cGMP-selective phosphodiesterase V inhibitors free of cardiovascular side-effects
PCT/EP2001/002485 WO2001068097A1 (en) 2000-03-14 2001-03-06 Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction

Publications (1)

Publication Number Publication Date
AU2001244192A1 true AU2001244192A1 (en) 2001-09-24

Family

ID=7634668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244192A Abandoned AU2001244192A1 (en) 2000-03-14 2001-03-06 Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction

Country Status (14)

Country Link
EP (1) EP1267877A1 (en)
JP (1) JP2003528056A (en)
AR (1) AR028250A1 (en)
AU (1) AU2001244192A1 (en)
BG (1) BG107077A (en)
BR (1) BR0109163A (en)
CZ (1) CZ20023078A3 (en)
DE (1) DE10012373A1 (en)
HU (1) HUP0300551A2 (en)
IL (1) IL151646A0 (en)
NO (1) NO20024364L (en)
RU (1) RU2002127413A (en)
SK (1) SK13232002A3 (en)
WO (1) WO2001068097A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
RU2308271C1 (en) * 2006-07-28 2007-10-20 Михаил Иосифович Коган Method for preventing the development of erectile dysfunction in patients after urethral trauma
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
RU2345778C1 (en) * 2007-04-26 2009-02-10 ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" Method for erectile dysfunction treatment in men
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
WO2009070584A1 (en) 2007-11-30 2009-06-04 Wyeth Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (en) 2010-11-08 2016-03-16 杨森制药公司 The purposes of 1,2,4-triazolo [4,3-a] pyridine derivate and the positive allosteric modulators as MGLUR2 acceptor thereof
IN2015DN00334A (en) 2012-06-18 2015-06-12 Dart Neuroscience Cayman Ltd
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
DK3096790T3 (en) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE
KR20220038826A (en) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
JP6420400B2 (en) * 2017-04-12 2018-11-07 ダート・ニューロサイエンス・(ケイマン)・リミテッド Substituted pyridine azolopyrimidin-5- (6H) -one compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
WO1993020077A1 (en) * 1992-04-03 1993-10-14 Yamanouchi Pharmaceutical Co., Ltd. Fused quinoxalinone derivative and pharmaceutical composition containing the same
DE4228095A1 (en) * 1992-08-24 1994-03-03 Asta Medica Ag New 4,5-dihydro-4-oxopyrrolo [1,2-a] quinoxalines and corresponding aza analogues and processes for their preparation
DE4338948A1 (en) * 1993-11-15 1995-05-18 Carlen Judith Treating erectile dysfunction without causing side-effects
DE19510965A1 (en) * 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation
DE19728301A1 (en) * 1997-07-03 1999-01-07 Dresden Arzneimittel Use of inhibitors of phosphodiesterase 4 for the treatment of allergic rhinitis

Also Published As

Publication number Publication date
BG107077A (en) 2003-05-30
AR028250A1 (en) 2003-04-30
WO2001068097A1 (en) 2001-09-20
NO20024364L (en) 2002-09-27
SK13232002A3 (en) 2003-05-02
IL151646A0 (en) 2003-04-10
NO20024364D0 (en) 2002-09-12
BR0109163A (en) 2002-11-26
EP1267877A1 (en) 2003-01-02
DE10012373A1 (en) 2001-09-20
JP2003528056A (en) 2003-09-24
CZ20023078A3 (en) 2003-03-12
RU2002127413A (en) 2004-02-27
HUP0300551A2 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
AU2001244192A1 (en) Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction
PL343794A1 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
AU6116701A (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
ZA200605901B (en) Pyrazolo [3,4-B] pyridine compounds, and their use as phosphodiesterase inhibitors
EP1027054A4 (en) Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2002102313A3 (en) Pyrimidine inhibitors of phosphodiesterase (pde) 7
IL161257A (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4(pde4) inhibitors
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
IL155386A0 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
SI1534707T1 (en) Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
EP1090644A3 (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator
HUP0300477A3 (en) Daily treatment for erectile dysfunction using a composition containing pde5 inhibitors
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
AU2002246924A1 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
AU2000270300A1 (en) Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
AU2002219247A1 (en) Use of levosimendan for treating erictile dysfunction